Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports ...

Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) recently released its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2024, as outlined in an 8-K filing with the ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report) and keeping the price target at ...

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023. Rigel expects to ...

Rigel's commercial portfolio has shown promising growth, particularly with its flagship products TAVALISSE and REZLIDHIA. In the third quarter of 2024, the company reported a strong revenue beat ...

KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel Pharmaceuticals KFDA greenlights Tavalisse, a ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to treat sickle cell disease (SCD). The trial aims to ...